证券日报网讯回盛生物11月5日在互动平台回答投资者提问时表示，公司产品结构丰富，以猪用药品为 核心，同时涵盖了家禽、水产、宠物、反刍等其他药品领域。在禽药板块，公司布局了多款中兽药制 剂，如板青颗粒、芪贞增免颗粒、清瘟解毒口服液等。上述产品临床疗效明显，但对禽流感病毒是否有 效还需进一步研究证明。 （文章来源：证券日报） ...

格隆汇8月6日丨回盛生物(300871.SZ)在投资者关系中表示，从总体结构来看，随着公司原料-制剂一体 化战略的逐步深化，上半年，原料药业务板块销售收入占比较上年同期提升十五个百分点。兽用制剂方 面，公司在进一步巩固猪用药品业务优势的同时，大力拓展家禽、水产、反刍等业务板块，猪、家禽、 水产板块产品销售收入均实现了较大幅度的增长。从靶动物分类来看，猪用药品收入占比约为80%。 ...

Group 1 - The core viewpoint of the article highlights the significant growth in the sales revenue of the raw material drug business segment, which has increased by 15 percentage points compared to the same period last year due to the company's integrated strategy of raw materials and formulations [1] - In the veterinary formulations sector, the company is not only consolidating its advantages in the pig medicine business but also actively expanding into poultry, aquaculture, and ruminant sectors, resulting in substantial revenue growth across these product lines [1] - Revenue from pig medicines accounts for approximately 80% of the total revenue from targeted animal categories, indicating a strong reliance on this segment [1]